2020 Volume 29 Issue 12 Pages 852-861
An understanding of the pathophysiology and angioarchitecture is essential to determine appropriate treatment for patients with dural arteriovenous fistulas (DAVFs). Presentations of DAVF can vary according to the location and venous drainage pattern, and the indication for treatment of DAVF should take the natural history of the condition into account. Most cases of DAVF can be treated with endovascular therapy whose treatment outcome has been improved in parallel with the advances in imaging, catheters, and embolic materials. Recently, Onyx has been approved as an embolic agent for DAVF in Japan. However, the current treatment strategy for DAVF is not uniform. Therefore, it is important to consider individualized treatment strategy that involves an understanding of the vascular anatomy and hemodynamics of each case.
